Division of Internal Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
JACC Heart Fail. 2022 Aug;10(8):571-580. doi: 10.1016/j.jchf.2022.05.006. Epub 2022 Jul 6.
With rising United States health care expenditure, estimating current spending for patients with heart failure (HF) informs the value of preventative health interventions.
The purpose of this study was to estimate current health care expenditure growth for patients with HF in the United States.
The authors pooled MEPS (Medical Expenditure Panel Survey) data from 2009-2018 to calculate total HF-related expenditure across clinical settings in the United States. A 2-part model adjusted for demographics, comorbidities, and year was used to estimate annual mean and incremental expenditures associated with HF.
In the United States, an average of $28,950 (2018 inflation-adjusted dollars) is spent per year for health care-related expenditure for individuals with HF compared with $5,727 for individuals without HF. After adjusting for demographics and comorbidities, a diagnosis of HF was associated with $3,594 in annual incremental expenditure compared with those without HF. HF-related expenditure increased from $26,864 annual per person in 2009-2010 to $32,955 in 2017-2018, representing a 23% rise over 10 years. In comparison, expenditure on myocardial infarction, type 2 diabetes mellitus, and cancer grew by 16%, 28%, and 16%, respectively. Most of the cost was related to hospitalization: $12,569 per year. Outpatient office-based care and prescription medications saw the greatest growth in cost over the period, 41% and 24%, respectively. Estimated incremental national expenditure for HF per year was $22.3 billion; total annual expenditure for adults with HF was $179.5 billion.
HF is a costly condition for which expenditure is growing faster than that of other chronic conditions.
随着美国医疗保健支出的增加,估算心力衰竭(HF)患者的当前支出有助于了解预防保健干预的价值。
本研究旨在估算美国心力衰竭患者当前的医疗保健支出增长情况。
作者从 2009 年至 2018 年汇总了 MEPS(医疗支出面板调查)数据,以计算美国不同临床环境下与 HF 相关的总支出。采用调整人口统计学、合并症和年份的两部分模型来估算与 HF 相关的年度平均和增量支出。
在美国,与没有 HF 的人相比,每年用于 HF 相关医疗保健支出的平均费用为 28950 美元(2018 年通胀调整后美元)。在调整人口统计学和合并症后,HF 的诊断与每年 3594 美元的增量支出相关。HF 相关支出从 2009-2010 年的每人每年 26864 美元增加到 2017-2018 年的 32955 美元,在 10 年内增长了 23%。相比之下,心肌梗死、2 型糖尿病和癌症的支出分别增长了 16%、28%和 16%。大部分费用与住院治疗有关:每年 12569 美元。在这段时间内,门诊办公室护理和处方药物的成本增长最大,分别为 41%和 24%。估计 HF 每年的全国增量支出为 223 亿美元;HF 成年患者的年总支出为 1795 亿美元。
HF 是一种昂贵的疾病,其支出增长速度超过其他慢性疾病。